# Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer

> **NCT00960336** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 59 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00960336
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960336, "Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00960336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*